BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules.
BridGene Biosciences has raised $28.0M in total funding. The most recent round was Series B. The last funding was announced in October 2025.
BridGene Biosciences's investors include Lapam Capital, Bayland Capital, Prox Ventures, Grains Valley Venture Capital, Kaitai Capital.
BridGene Biosciences is headquartered in Sunnyvale, United States.
BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules.
BridGene Biosciences is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BridGene Biosciences — Funding & Investors." VCBacked, October 16, 2025, https://www.vcbacked.co/company/bridgene-biosciences. Accessed September 15, 2026.
VCBacked. (2025). BridGene Biosciences — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/bridgene-biosciences
{{cite web |title=BridGene Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/bridgene-biosciences |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated